← Evidence map

ArticleOncogenesis2025

GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells.

Le Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40651944